Log in to search using one of your social media accounts:

This page shows you the latest news items in this category. This is page number 2.

'I'm the real life Jaws': Student, 36, has condition which means his jaw bone won't stop growing
Richard Moore, from Wigan, has acromegaly - meaning some of his bones continue to increase in size after the skeleton and other organs have finished growing. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2014 Category: Consumer Health News Source Type: news

2014 ASPIRE Young Investigator Research Awards in Endocrinology
The mission of the 2014 ASPIRE Young Investigator Research Awards in Endocrinology is to advance the medical knowledge of the fundamental mechanisms of disease, mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders. Funding will be provided to research proposals that seek to explore basic, translational, or clinical research in the area of endocrine disease in adults and children: Clinical and Translational Research in the GH and IGF-I Axis Morbidity and Mortality in Patients with Acromegaly Novel measures of growth hormone treatment benefits S...
Source: Society for Endocrinology - May 21, 2014 Category: Endocrinology Source Type: news

Pasireotide LAR for Acromegaly but Hyperglycemia a DrawbackPasireotide LAR for Acromegaly but Hyperglycemia a Drawback
Pasireotide LAR improves response in acromegaly patients poorly controlled on first-generation somatostatins, but hyperglycemia remains an issue as the agent awaits regulatory approval for this indication. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 15, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

New Funding for Clinical Endocrinology Quality Improvement Projects available from the Clinical Endocrinology Trust
The Clinical Endocrinology Trust has long supported Endocrine Audit projects within the UK.  Recent examples include the UK Acromegaly Database, the CaHASE audit of adults with CAH, and a BTA study of teenage iodine status across the UK. The Trustees now invite further applications from Societies or Endocrine Centres within the UK.  Preference will be given to projects involving multicentre collaborations.  We are particularly interested in receiving applications related to areas of endocrinology the Trust has not supported previously.  A total sum of £50,000 is avail...
Source: Society for Endocrinology - April 25, 2014 Category: Endocrinology Source Type: news

Acromegaly, IGF1 bioactivity, and S-Klotho
The value of measuring IGF1 bioactivity in active acromegaly is unknown. Soluble Klotho (S-Klotho) level is elevated in active acromegaly and it has been suggested that S-Klotho can inhibit activation of the IGF1 receptor (IGF1R). A cross-sectional study was carried out in 15 patients with active acromegaly, finding that IGF1 bioactivity was within the reference range in a considerable number of subjects with active acromegaly and that elevated S-Klotho levels may have reduced IGF1 bioactivity. Moreover, IGF1 bioactivity was more strongly related to physical measures of QoL than total IGF1, suggesting that IGF1 bioactivity...
Source: Society for Endocrinology - April 25, 2014 Category: Endocrinology Source Type: news

Sharing your patient record can help researchers save and improve lives
The Society for Endocrinology is supporting a new campaign to raise awareness about the importance of sharing data from patient records with researchers. By allowing researchers access to the information contained within our records, we can contribute towards understanding the causes of disease and develop new and better medicines. Access to health data has played a major role in the Society's own project, such as the UK Acromegaly Register. This project, initially set up in 1997, collects prospective and retrospective data on patients with acromegaly to assess outcomes of surgery, radiotherapy and medica...
Source: Society for Endocrinology - January 14, 2014 Category: Endocrinology Source Type: news

New research on sauropod gigantism summarized in publicly available collection
(Johannes Gutenberg Universitaet Mainz) Dr. Eva Maria Griebeler of Johannes Gutenberg University Mainz has now shown that the hypothesis is inaccurate that their body size was limited only because the associated rise in body temperature could have resulted in potential overheating. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 14, 2014 Category: Biology Source Type: news

Growth Disorder Tx Has Room for Improvement (CME/CE)
(MedPage Today) -- Although control of the disease has improved over the past few decades, about a quarter of patients with acromegaly aren't hitting treatment targets, British researchers found. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 11, 2013 Category: Pediatrics Source Type: news

UK Acromegaly Register: drugs fail to meet hormone targets in control of rare growth disorder
A study by the Society for Endocrinology UK Acromegaly Register published in Clinical Endocrinology assesses medical treatment of acromegaly in routine clinical practice over 30 years. Full article Clinical Endocrinology is the Society for Endocrinology's official clinical journal. (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 10, 2013 Category: Endocrinology Source Type: news

A bigger fish for palaeontogists to fry…
A chance find in a quarry led to the discovery that Leedsichthys problematicus grew up to 50ft long – double previous estimatesAn international team of scientists has uncovered the remains of the world's largest fish. The 50ft Leedsichthys problematicus swam the oceans of the Jurassic era more than 160m years ago, sweeping up shoals of plankton through giant, mesh-covered gills. Leedsichthys was eventually wiped out by the same catastrophe that killed the dinosaurs 66m years ago.The discovery by the team – led by Professor Jeff Liston of the National Museums of Scotland – is intriguing because it reveals that just as...
Source: Guardian Unlimited Science - August 24, 2013 Category: Science Authors: Robin McKie Tags: Evolution Dinosaurs Editorial The Observer Fossils Zoology Science Source Type: news

Discuss quality of life with acromegaly patients
Read the full story on MD Consult: Discuss quality of life with acromegaly patients (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - July 24, 2013 Category: Journals (General) Source Type: news

What Causes Hypercalcemia?
Discussion Calcium homeostasis is regulated by mechanisms involving the absorption from the gastrointestinal tract, bone deposition and resorption, and renal excretion. To review Vitamin D homeostasis click here. Serum calcium is found in three forms: free (47%), protein bound (43%) and diffusable calcium complexes (10%). The protein binding proteins are albumin (80%) and globulin (20%). The free calcium is the most important biologically. Acidosis also increases free calcium and alkalosis decreases free calcium. Problems associated with hypercalcemia include nausea, emesis, abdominal pain, constipation, polyuria, dehydra...
Source: PediatricEducation.org - March 25, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Basel, 18 February 2013-Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Roche, Chiasma ink deal on hormone disorder treatment (Reuters, 18 February 2013)
Drugmakers Roche and Chiasma have announced plans to work together to develop and market an oral formulation of octreotide for patients with acromegaly. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 19, 2013 Category: Endocrinology Source Type: news

Roche, Chiasma partner to develop, commercialise Octreolin
Roche and Chiasma have partnered to develop and commercialise Octreolin, an investigational oral regimen for acromegaly and neuroendocrine tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - February 19, 2013 Category: Pharmaceuticals Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors
BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered i... Biopharmaceuticals, Endocrinology, LicensingChiasma, Roche Group, Octreolin, acromegaly (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 18, 2013 Category: Pharmaceuticals Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Roche and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection. Octreolin is currently in a pivotal phase 3 clinical trial for acromegaly. Under the terms of the agreement, Roche received a worldwide exclusive license to Octreolin, and will assume responsibility for th...
Source: Roche Investor Update - February 18, 2013 Category: Pharmaceuticals Source Type: news

UK Acromegaly Register Annual General Meeting
We would like to invite you to the UK Acromegaly Register AGM that will take place during the SfE BES 2013 conference. The AGM will take place in Queens Suite A, Harrogate International Centre, 12:00noon-13:00 on Tuesday 19 March 2013, and will be followed by an Ipsen sponsored symposium on acromegaly from 13:00-14:00. (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 11, 2013 Category: Endocrinology Source Type: news

Former model with rare growth disease dies
Acromegaly is a disorder in which there is too much growth hormone in the body (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 17, 2013 Category: Consumer Health News Source Type: news

Teijin Pharma to Launch Ipsen?s Somatuline Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan
Tokyo, Japan / Paris, France, January 17, 2013 --- Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Ipsen (Euronext: IPN; ADR: IPSEY), today announced the launch of Somatuline® 60/90/120 mg for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 17, 2013 Category: Pharmaceuticals Source Type: news

Tanya Angus, woman who couldn't stop growing, dies at 34
Tanya Argus became an advocate for acromegaly, a disorder that causes too much growth hormone in body (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 16, 2013 Category: Consumer Health News Source Type: news